• 1
    LeRoy EC: Pathogenesis of scleroderma (systemic sclerosis). J Invest Dermatol 79 (suppl 1): 87S89S, 1982
  • 2
    Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Goto K, Yazaki K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 32: 411415, 1988
  • 3
    Yanagisawa M, Masaki T: Endothelin, a novel endothelium-derived peptide: pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Phrmacol 38: 18771883, 1989
  • 4
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581590, 1980
  • 5
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 12711277, 1982
  • 6
    Suzuki N, Matsumoto H, Kitada C, Masaki T, Fujino M: A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods 118: 245250, 1989
  • 7
    Kahaleh MB: “Endothelin”—an endothelial-dependent vasoconstrictor in scleroderma. Arthritis Rheum 32 (suppl 4): S76, 1989
  • 8
    Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Comun 161: 562567, 1989
  • 9
    Furst DE, David JA, Clements PJ, Chopra SL, Theofilopoulos AN, Chia D: Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis. Arthritis Rheum 24: 14031408, 1981